More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...

Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory ...

University of Cincinnati reported positive Phase 2 melanoma trial results, with a third of patients responding to a combined ...

Metastatic melanoma cells that have spread to lymph nodes survive by relying on a protein called ferroptosis suppressor ...

Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

Recall, at the 2025 SNO/ASCO CNS Metastases conference in August, ReSPECT-LM Phase 1 single dose escalation trial data showed: REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented promising ...

Neuroblastoma RAS viral oncogene homolog (NRAS)-mutant melanoma is an aggressive form of skin cancer that develops because of ...

A gene mutation known to develop into one of Queensland’s deadliest cancers could be hiding in skin undetected.

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators reveals how melanoma, the deadliest form of skin ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...